FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer By Ogkologos - July 4, 2025 689 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Representation, retention and hope – how a mentorship scheme is helping... October 25, 2022 Researchers Discover Way to Help Immunotherapy Better Target Solid Tumors Like... January 5, 2021 How Finding the Right Primary Care Physician During Cancer Has Helped... March 24, 2021 FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma November 6, 2025 Load more HOT NEWS Though the Pandemic Has Slowed, Many Are Still Struggling to Put... Mesothelioma Awareness Day: Spotlight on the PrE0506/DREAM3R Clinical Trial Cancer Research UK releases 2022 gender and ethnicity pay gap reports Journalist Is Now Cancer-Free After Receiving Diagnosis On Facebook Live
